Skip to main content
Top
Published in: Annals of Surgical Oncology 4/2014

01-04-2014 | Breast Oncology

Effect of Margin Width on Local Recurrence in Triple-Negative Breast Cancer Patients Treated with Breast-Conserving Therapy

Authors: Melissa Pilewskie, MD, Alice Ho, MD, Emily Orell, BS, Michelle Stempel, MPH, Yu Chen, BS, Anne Eaton, MS, Sujata Patil, PhD, Monica Morrow, MD

Published in: Annals of Surgical Oncology | Issue 4/2014

Login to get access

Abstract

Background

The effect of increasing negative margin width after breast-conserving therapy (BCT) on local recurrence (LR) is controversial. LR rates vary by subtype, with the highest rates seen in triple-negative breast cancer (TNBC). This study examined LR rates in relationship to margin width in TNBC treated with BCT.

Methods

Women with TNBC who underwent BCT between 1999 and 2009 were identified. Margins were defined as positive (ink on tumor), 0.1–2.0, and 2 mm. Patients with positive margins were excluded. Statistical comparisons were by t test, Fisher’s exact test, and Wilcoxon rank sum test. Cumulative incidence of LR was compared by competing-risks methodology.

Results

Of 535 cancers, 71 had margins ≤2 mm and 464 had margins >2 mm. At a median follow-up of 84 months (range 8–165 months), there were 37 local, 18 regional, and 77 distant recurrences or deaths as first events. Ten patients had a locoregional recurrence before planned radiotherapy and were excluded from cumulative incidence analyses. The cumulative incidence of LR at 60 months for margins ≤2 mm was 4.7 % (95 % confidence interval 0–10.0) and for >2 mm was 3.7 % (1.8, 5.5) (p = 0.11). After controlling for chemotherapy and tumor size, there was no difference in LR between the two margin groups (p = 0.06). A difference in the risk of distant recurrence or death was not observed (p = 0.53).

Conclusions

Margin width of >2 mm was not associated with reduced LR rates. These data support a negative margin definition of no ink on tumor, even in this high-risk TNBC cohort.
Literature
1.
go back to reference Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.PubMedCrossRef Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.PubMedCrossRef
2.
go back to reference Bouganim N, Tsvetkova E, Clemons M, et al. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat. 2013;139:603–6.PubMedCrossRef Bouganim N, Tsvetkova E, Clemons M, et al. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat. 2013;139:603–6.PubMedCrossRef
3.
go back to reference Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg. 2002;184:383–93.PubMedCrossRef Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg. 2002;184:383–93.PubMedCrossRef
4.
go back to reference Azu M, Abrahamse P, Katz SJ, et al. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol. 2010;17:558–63.PubMedCentralPubMedCrossRef Azu M, Abrahamse P, Katz SJ, et al. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol. 2010;17:558–63.PubMedCentralPubMedCrossRef
5.
go back to reference Lovrics PJ, Gordon M, Cornacchi SD, et al. Practice patterns and perceptions of margin status for breast conserving surgery for breast carcinoma: National Survey of Canadian General Surgeons. Breast. 2012;21:730–4.PubMedCrossRef Lovrics PJ, Gordon M, Cornacchi SD, et al. Practice patterns and perceptions of margin status for breast conserving surgery for breast carcinoma: National Survey of Canadian General Surgeons. Breast. 2012;21:730–4.PubMedCrossRef
6.
go back to reference Hassani A, Griffith C, Harvey J. Size does matter: High volume breast surgeons accept smaller excision margins for wide local excision—a national survey of the surgical management of wide local excision margins in UK breast cancer patients. Breast. 2013;22:718–22.PubMedCrossRef Hassani A, Griffith C, Harvey J. Size does matter: High volume breast surgeons accept smaller excision margins for wide local excision—a national survey of the surgical management of wide local excision margins in UK breast cancer patients. Breast. 2013;22:718–22.PubMedCrossRef
7.
go back to reference Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46:3219–32.PubMedCrossRef Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46:3219–32.PubMedCrossRef
8.
go back to reference Lowery AJ, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133:831–41.PubMedCrossRef Lowery AJ, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133:831–41.PubMedCrossRef
9.
go back to reference Groot G, Rees H, Pahwa P, et al. Predicting local recurrence following breast-conserving therapy for early stage breast cancer: the significance of a narrow (</=2 mm) surgical resection margin. J Surg Oncol. 2011;103:212–6.PubMedCrossRef Groot G, Rees H, Pahwa P, et al. Predicting local recurrence following breast-conserving therapy for early stage breast cancer: the significance of a narrow (</=2 mm) surgical resection margin. J Surg Oncol. 2011;103:212–6.PubMedCrossRef
10.
go back to reference Chen W, Stroom J, Sonke JJ, et al. Impact of negative margin width on local recurrence in breast conserving therapy. Radiother Oncol. 2012;104:148–54.PubMedCrossRef Chen W, Stroom J, Sonke JJ, et al. Impact of negative margin width on local recurrence in breast conserving therapy. Radiother Oncol. 2012;104:148–54.PubMedCrossRef
11.
go back to reference Hattangadi-Gluth JA, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012;82:1185–91.PubMedCrossRef Hattangadi-Gluth JA, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012;82:1185–91.PubMedCrossRef
12.
go back to reference Panoff JE, Hurley J, Takita C, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat. 2011;128:899–906.PubMedCrossRef Panoff JE, Hurley J, Takita C, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat. 2011;128:899–906.PubMedCrossRef
13.
go back to reference Kim MM, Dawood S, Allen P, et al. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012;118:4936–43.PubMedCentralPubMedCrossRef Kim MM, Dawood S, Allen P, et al. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012;118:4936–43.PubMedCentralPubMedCrossRef
14.
go back to reference Russo AL, Arvold ND, Niemierko A, et al. Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat. 2013;140:353–61.PubMedCrossRef Russo AL, Arvold ND, Niemierko A, et al. Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat. 2013;140:353–61.PubMedCrossRef
15.
go back to reference Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–42.PubMedCrossRef Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–42.PubMedCrossRef
16.
go back to reference Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor–negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14:1982–92.PubMed Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor–negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14:1982–92.PubMed
17.
go back to reference Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef
18.
go back to reference Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620–30.PubMedCrossRef Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620–30.PubMedCrossRef
19.
go back to reference Adkins FC, Gonzalez-Angulo AM, Lei X, et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011;18:3164–73.PubMedCrossRef Adkins FC, Gonzalez-Angulo AM, Lei X, et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011;18:3164–73.PubMedCrossRef
20.
go back to reference Parker CC, Ampil F, Burton G, et al. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery. 2010;148:386–91.PubMedCrossRef Parker CC, Ampil F, Burton G, et al. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery. 2010;148:386–91.PubMedCrossRef
21.
go back to reference Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1–2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20:3469–76.PubMedCrossRef Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1–2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20:3469–76.PubMedCrossRef
22.
go back to reference Morrow M, Jagsi R, Alderman AK, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA. 2009;302:1551–6.PubMedCrossRef Morrow M, Jagsi R, Alderman AK, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA. 2009;302:1551–6.PubMedCrossRef
23.
go back to reference McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in reexcision following breast conservation surgery. JAMA. 2012;307:467–75.PubMedCrossRef McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in reexcision following breast conservation surgery. JAMA. 2012;307:467–75.PubMedCrossRef
24.
go back to reference Al-Ghazal SK, Blamey RW, Stewart J, et al. The cosmetic outcome in early breast cancer treated with breast conservation. Eur J Surg Oncol. 1999;25:566–70.PubMedCrossRef Al-Ghazal SK, Blamey RW, Stewart J, et al. The cosmetic outcome in early breast cancer treated with breast conservation. Eur J Surg Oncol. 1999;25:566–70.PubMedCrossRef
25.
go back to reference Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.PubMedCrossRef Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.PubMedCrossRef
26.
go back to reference Pogoda K, Niwinska A, Murawska M, et al. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30:388.PubMedCentralPubMedCrossRef Pogoda K, Niwinska A, Murawska M, et al. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30:388.PubMedCentralPubMedCrossRef
Metadata
Title
Effect of Margin Width on Local Recurrence in Triple-Negative Breast Cancer Patients Treated with Breast-Conserving Therapy
Authors
Melissa Pilewskie, MD
Alice Ho, MD
Emily Orell, BS
Michelle Stempel, MPH
Yu Chen, BS
Anne Eaton, MS
Sujata Patil, PhD
Monica Morrow, MD
Publication date
01-04-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 4/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3416-5

Other articles of this Issue 4/2014

Annals of Surgical Oncology 4/2014 Go to the issue